Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin
Mary Alma Welch,(1) PA-C, Joanne C. Ryan,(2) PhD, RN, and Ilene Ann Galinsky,(3) BSN, MSN, ANP-C
(1)MD Anderson Cancer Center, Houston, Texas; (2)Pfizer Inc, New York, New York; (3)Dana Farber Cancer Institute, Boston, Massachusetts
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Mary Alma Welch, PA-C, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
J Adv Pract Oncol 2017;8:631–636 |
© 2017 Harborside Press®
For access to the full length article, please sign in